NCT04435158View on ClinicalTrials.gov

A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

July 18, 2022

Study Completion Date

July 18, 2022

Conditions

Osteoporosis

Interventions

DRUG

SHR-1222

Pharmaceutical form: water injection Route of administration: subcutaneous injection

DRUG

Placebo

Pharmaceutical form: water injection Route of administration: subcutaneous injection

Trial Locations (1)

Unknown

2nd Xiangya Hospital , Chinese Academy of Medical Sciences, Changsha

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04435158 - A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients | Biotech Hunter | Biotech Hunter